- Conditions
- Idiopathic Parkinson Disease
- Interventions
- VTX3232
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Placebo, VTX3232 30 mg, Placebo in combination with semaglutide, VTX3232 30 mg in combination with semaglutide
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Lake Forest, California • Long Beach, California + 9 more